Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy

Andrius Žučenka • 7 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Cytarabine Glasdegib Venetoclax

Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who fail venetoclax-based salvage therapies, commenting on poor prognosis. Dr Zucenka reports that venetoclax re-initiation or low-dose cytarabine plus glasdegib may be possible options for patients in this subgroup. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Andrius Žučenka

2:18
VEN-AZA versus intensive chemotherapy as bridging therapy in patients with MDS
Andrius Žučenka • 8 Dec 2023
3:52
Maintenance therapy with revumenib following alloSCT in KMT2Ar and NPM1-mutated acute leukemias
Andrius Žučenka • 8 Dec 2023
2:27
Challenges with managing the high rates of infections seen in patients with AML
Andrius Žučenka • 8 Dec 2023
2:12
Approaching patients with FLT3-mutated AML who are ineligible for high-intensity chemotherapy
Andrius Žučenka • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals